Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01369628 · ClinicalTrials.gov registry record · Phase 1
Atacicept in Lupus Nephritis Patients Taking Stable Regimen of Mycophenolate Mofetil
A Phase 1 study, sponsored by EMD Serono.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT01369628 is a Phase 1 study that was terminated before completion, run by EMD Serono. The registered enrollment target is 1 participants.
The verdict
NCT01369628, a Phase 1 study, was terminated before completion, sponsored by EMD Serono.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The sponsor electively terminated the study because the risk mitigation measures, deemed necessary after an unforeseen safety event, could not be effectively implemented within this protocol while maintaining study timelines within a reasonable time frame.
Interventions
- DRUG Atacicept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2011-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01369628
The ClinicalTrials.gov registry entry for NCT01369628 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Atacicept is the first listed.
NCT01369628 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01369628 about?
NCT01369628 is a clinical study titled "Atacicept in Lupus Nephritis Patients Taking Stable Regimen of Mycophenolate Mofetil". The sponsor electively terminated the study because the risk mitigation measures, deemed necessary after an unforeseen safety event, could not be effectively implemented within this protocol while maintaining study timelines within a reasonable time frame.
What is the current status of trial NCT01369628?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2011-06.
What interventions are being tested in trial NCT01369628?
The interventions under investigation include: Atacicept (DRUG).
Who is sponsoring clinical trial NCT01369628?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.